BioFluidica Next-Generation Liquid Biopsy Platform Uncovers Undiagnosed HER2+ Patients

SAN DIEGO, June 24, 2022 /PRNewswire/ — Biofluidica today announced the results of a breast cancer study comparing invasive needle biopsies with their non-invasive, highly sensitive Next-Generation Liquid Biopsy platform, LiquidScan™ to detect HER2 positive (HER2+) patients. Patients…

Click here to view original post